FSFI desire score raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-21 and is reviewed periodically as new material appears.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
=== Quantum mechanics effects === Quantum mechanics effects become noticeable for nanoscale objects. They include quantum confinement in semiconductor particles, localized surface plasmons in some metal particles, and superparamagnetism in magnetic materials. Quantum dots are nanoparticles of semiconducting material that are small enough (typically sub 10 nm or less) to have quantized electronic energy levels. Quantum effects are responsible for the deep-red to black color of gold or silicon nanopowders and nanoparticle suspensions. Absorption of solar radiation is much higher in materials composed of nanoparticles than in thin films of continuous sheets of material. In both solar PV and solar thermal applications, by controlling the size, shape, and material of the particles, it is possible to control solar absorption. Core-shell nanoparticles can support simultaneously both electric and magnetic resonances, demonstrating entirely new properties when compared with bare metallic nanoparticles if the resonances are properly engineered. The formation of the core-shell structure from two different metals enables an energy exchange between the core and the shell, typically found in upconverting nanoparticles and downconverting nanoparticles, and causes a shift in the emission wavelength spectrum. By introducing a dielectric layer, plasmonic core (metal)-shell (dielectric) nanoparticles enhance light absorption by increasing scattering.
Mass popular support and protest meant that these five became known as the Tolpuddle martyrs, and they were eventually pardoned. The population tripled to more than a million migrants over the Australian gold rushes of 1851, and protests broke out against the government's attempt to impose a licence fee for working to search for gold (whether or not gold was found). In 1854, when the fee was £2 for 3 months, strict and brutal enforcement led to the Eureka Stockade at Ballarat, where rebels demanded an end to the fee, democratic representation in the government, and took up arms. Though the stockade was broken, and its leaders killed or arrested and put on trial, juries acquitted all, the gold licence fee was replaced with an export duty, and miners won the right to vote in the Victorian Legislative Assembly. Yet labour rights throughout Australian colonies were scant. Laws were systematically discriminatory, particularly based on gender and race, entrenched in the White Australia policy from the Immigration Restriction Act 1901. The right to organise unions was precarious, without any positive right to take collective action for fair work, and there were no legislative rights to fair wages or job security. Instead, responding to the 1890 Australian maritime dispute, the 1892 Broken Hill miners' strike and others, South Australia, New Zealand, New South Wales, and finally the federation sought to replace industrial conflict and strikes with a system of arbitration.
== Mechanism == Rather than being classified as an "autoimmune" disease, SJIA is thought to be an autoinflammatory condition. This is due to the lack of evidence linking any particular antigen-antibody dyad to the pathogenesis or etiology of sJIA. Additionally, sJIA presents with fevers, rash, and multisystem involvement, just like other autoinflammatory illnesses. Autoimmune diseases are adaptive immune system disorders with autoantibodies, while autoinflammatory diseases are caused by innate immune system dysfunction. Several studies show that the innate immune system has a role in sJIA pathogenesis by producing pro-inflammatory cytokines such as interleukin-1, interleukin-6, interleukin-7, interleukin-8, interleukin-18, macrophage migration inhibitory factor, and tumor necrosis factor (TNF). Cytokines have a strong correlation with disease-related systemic characteristics. Elevated interleukin-6 levels are associated with anemia, thrombocytosis, osteoporosis, and delayed growth. Interleukin-1b also contributes significantly to disease etiology.
=== December === December 3 – Nidal Hasan is scheduled to be executed. If carried out, he would be the first sitting member of the United States Armed Forces to be executed since John A. Bennett was executed in 1961 for rape and attempted murder and the first person executed publicly in the U.S. since that of Roscoe Jackson in 1937.
Most modern nuclear weapons utilize 238U as a "tamper" material (see nuclear weapon design). A tamper which surrounds a fissile core works to reflect neutrons and to add inertia to the compression of the 239Pu charge. As such, it increases the efficiency of the weapon and reduces the critical mass required. In the case of a thermonuclear weapon, 238U can be used to encase the fusion fuel, the high flux of very energetic neutrons from the resulting fusion reaction causes 238U nuclei to split and adds more energy to the "yield" of the weapon. Such weapons are referred to as fission-fusion-fission weapons after the order in which each reaction takes place. An example of such a weapon is Castle Bravo. The larger portion of the total explosive yield in this design comes from the final fission stage fueled by 238U, producing enormous amounts of radioactive fission products. For example, an estimated 77% of the 10.4-megaton yield of the Ivy Mike thermonuclear test in 1952 came from fast fission of the depleted uranium tamper. Because depleted (or natural) uranium has no critical mass, it can be added to thermonuclear bombs in almost unlimited quantity. The Soviet Union's test of the Tsar Bomba in 1961 produced "only" 50 megatons of explosive power, over 90% of which came from fusion because the 238U final stage had been replaced with lead. Had 238U been used instead, the yield of the Tsar Bomba could have been well above 100 megatons, and it would have produced nuclear fallout equivalent to one third of the global total that had been produced up to that time.
Sources: en.wikipedia.org
== Function == The protein encoded by this gene is an enzyme that belongs to the subtilisin-like proprotein convertase family. The members of this family are proprotein convertases that process latent precursor proteins into their biologically active products. This encoded protein is a calcium-dependent serine endoprotease that can efficiently cleave precursor proteins at their paired basic amino acid processing sites. Some of its substrates are: proparathyroid hormone, transforming growth factor beta 1 precursor, proalbumin, pro-beta-secretase, membrane type-1 matrix metalloproteinase, beta subunit of pro-nerve growth factor and von Willebrand factor. A furin-like pro-protein convertase has been implicated in the processing of RGMc (also called hemojuvelin), a gene involved in a severe iron-overload disorder called juvenile hemochromatosis. Both the Ganz and Rotwein groups demonstrated that furin-like proprotein convertases (PPC) are responsible for conversion of 50 kDa HJV to a 40 kDa protein with a truncated COOH-terminus, at a conserved polybasic RNRR site. This suggests a potential mechanism to generate the soluble forms of HJV/hemojuvelin (s-hemojuvelin) found in the blood of rodents and humans. The furin substrates and the locations of furin cleavage sites in protein sequences can be predicted by two bioinformatics methods: ProP and PiTou.
January 1916: creation of Secret Inter-Party Citizen's Committee (pl. Tajny Międzypartyjny Komitet Obywatelski) formed by members of the German Reichstag of Polish nationality. July 1918: a network of local Citizens' Committees is created on area of Prussian Partition. 11 October 1918: Polish organizations in the German Empire publicise common documents in which they declare the will to create independent Polish state and, in effect, revolution. 9 November 1918: beginning of the German Revolution, which also occurred in Greater Poland. Poles organized secret military structures in the Poznań garrison, Jarocin and Inowrocław. 10 November 1918: events of the so-called Republic of Ostrów. 11 November 1918 Armistice signed, ending the hostilities of World War I. The Citizens' Guard (Straż Obywatelska), renamed a few days later to the People's Guard (Straż Ludowa), comes out from the underground. The mayor of Poznań (Posen), Ernst Wilms, is removed from office. German military authorities give permission for functioning of the People's Guard to keep peace in the Province of Posen. 12 November 1918 The Central Citizen's Committee, later renamed to the Supreme People's Council (Naczelna Rada Ludowa, NRL), creates temporary "government-in-waiting" Commission (Komisariat): Stanisław Adamski, Wojciech Korfanty, and Adam Poszwiński. Jarogniew Drwęski becomes the Mayor of Poznań. 13 November 1918 Commission of the High People's Council calls citizens of German portion of Poland to keep calm in spite of the revolution.
== Safety == DNCB induces a type IV hypersensitivity reaction in almost all people exposed to it, so it is used medically to assess the T cell activity in patients. This is a useful diagnostic test for immunocompromised patients. It can also be used to treat warts. DNCB can cause contact dermatitis.
The specific matchups involving the third-place teams depended on which eight third-place teams qualified for the round of 32, but not on their relative rankings. The 495 possible combinations were published in Annex C of the tournament regulations. Because of the specific combination of qualified teams, option number 67 of annex C was applicable.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.